Biotech Stock Powers Higher on COVID-19 Clinical Trial

Lattice Biologics Ltd. (TSXV:LBL), a biotech stock, climbed after announcing that it has begun enrolling patients in its Phase 1 clinical trial for the treatment of SARS

Sean Mason | March 17, 2020 | SmallCapPower

A pending clinical trial for treating a COVID-19 related illness lifted shares of a Canada-listed biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, March 17, 2020 (as of 11:30 am EST):

Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, surged 56% to $0.14 on Tuesday after announcing that it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.

Win Big With Our Small Cap Picks

 

As well, shares of Visionstate Corp. (TSXV:VIS) gained 33% to $0.065 as the Company said it has seen a marked uptick of inquiries about its WANDA IoT solution in the wake of the coronavirus outbreak. WANDA is a smart tablet that is mounted at the entrance of public restrooms and monitors cleaning activities to ensure that those efforts are compliant with required procedures in order to meet high standards of cleanliness.

Elixxer Ltd. (TSXV:ELXR), meanwhile, reported that its Italian pharmaceutical partner, Freia Farmaceutici, has successfully launched its topical hand sanitizer, Dermogel, in Italy with their initial block of 10,000 units. Elixxer stock moved up 40% to $0.035 following the announcement.

See more Small and Micro Cap Market Movers Daily from Sean Mason. Tomorrow’s big stock market winners could be found here today!

Hi, did you know SmallCapPower accepts blog submissions? You can contact me here

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below: